Company news
Klygefa approved for weekly self-injection in myasthenia gravis

Clinical takeaway: Offer weekly self-administration as a treatment option for eligible adults. Prescribers must enroll in the restricted safety program and counsel patients about the risk of serious meningococcal infections.
On November 16, 2026, FDA approved Klygefa (gefurulimab-gaks), the first dual-binding nanobody inhibitor of complement component 5 (C5), for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
Adults with gMG can struggle to speak or swallow as muscle weakness disrupts daily life. A randomized trial of Klygefa tested whether another C5 inhibitor could ease that burden.
PREVAIL enrolled 260 adults with AChR antibody-positive gMG in a phase 3, double-blind trial. Patients received weekly subcutaneous Klygefa or placebo for 26 weeks while continuing stable background therapy. Those who completed the trial could enter an ongoing open-label extension.
At week 26, Myasthenia Gravis Activities of Daily Living scores fell by an adjusted mean of 4.2 points with Klygefa versus 2.6 points with placebo, a statistically significant 1.6-point difference favoreing Klygefa. In addition, 65.5% of patients receiving Klygefa achieved at least a three-point improvement on the daily activities scale, compared with 52.2% receiving placebo.
On the clinician-assessed Quantitative Myasthenia Gravis scale, scores fell by an adjusted mean of 4.5 points with Klygefa versus 2.4 points with placebo. At least a five-point improvement occurred in 46.3% receiving Klygefa versus 25.2% receiving placebo.
The most common adverse reactions with Klygefa were injection site reactions in 12%, back pain in 8% and vomiting in 5%. Klygefa carries a boxed warning for serious, potentially fatal meningococcal infections, a risk with C5 inhibitors. Patients should be vaccinated at least two weeks before starting, or receive antibiotics if treatment must begin urgently, and risk persists despite vaccination. Prescribers must enroll in the restricted safety program, called a Risk Evaluation and Mitigation Strategy (REMS). Serious infections, including fatal cases, occurred during the trial and its extension.
Patients who prefer self-injection can choose between weekly Klygefa and daily zilucoplan (Zilbrysq), another C5 inhibitor. Eculizumab (Soliris) and ravulizumab (Ultomiris) are given as intravenous maintenance infusions every two weeks and every eight weeks, respectively. Superior efficacy or safety of any one has not been established.
“gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals,” said Kelly Gwathmey, MD, associate professor at Columbia University Vagelos College of Physicians and Surgeons, in the company press release.
Sources: AstraZeneca. (2026 Nov 16). Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients; Gwathmey KG, et al. (2026 Jul 27) JAMA Neurol. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial